Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This phase II trial tests how well nemtabrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as CLL or SLL at abnormal levels. This may help keep cancer cells from growing and spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for c

Trial Details

NCT ID

NCT07557056

Phase

PHASE2

Sponsor

Jennifer Woyach

Status

RECRUITING

Cancer Type

Leukemia

Interventions

Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Computed Tomography
Nemtabrutinib
Questionnaire Administration

Locations (sample)

Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

Confirmed diagnosis of CLL/SLL meeting criteria established in the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines
Is an individual of any sex/gender, who is at least 18 years of age on the day of signing informed consent
Participants must have treatment-naïve CLL/SLL. Palliative loco-regional radiotherapy, rituximab for autoimmune conditions, or corticosteroids for …
Participants must meet criteria for treatment as defined by 2018 iwCLL guidelines which includes at least one of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →